Abstract
In the absence of sufficient testing capacity for COVID-19, a substantial number of infecteds are expected to remain undetected, and hence, are not quarantined. This, in turn, defeats the whole purpose of non-medical containment measures, like quarantine, lockdown, travel ban, physical distancing etc., by keeping the average reproduction rate above 1. To stress upon the importance of extensive random testing for breaking the chains of transmissions, we have formulated a detailed framework for carrying out cost-effectiveness analysis (CEA) of extensive random testing in comparison to targeted testing (the existing testing policy followed by most countries). This framework can be easily extended for CEA of any other non-medical or even medical interventions for containing epidemics.
We have developed a new version of the basic susceptible-infected-removed (SIR) compartmental model, called the susceptible-infected (quarantined/ free) - recovered-deceased [SI(Q/F)RD] model, to incorporate the impact of undetected cases on the transmission dynamics of the epidemic. Further, we have presented a Dirichlet-Beta state-space formulation of the SI(Q/F)RD model for the estimation of its parameters using posterior realizations from Gibbs sampling procedure. As an application, the proposed methodology is implemented to forecast the COVID-19 transmission in California and Florida, and further carry out CEA of extensive random testing over targeted testing.
Highlights
Estimated values of excess deaths associated with COVID-19 are used to account for underreporting, and for calibrating data to obtain actual counts of cases.
A new flexible version of SIR compartmental model, called SI(Q/F)RD, is introduced to facilitate in the CEA exercise.
Dirichlet-Beta state-space formulation of the SI(Q/F)RD model is used to predict the transmission dynamics of the epidemic.
CEA is conducted in terms of outcome (reduction in infections and deaths) and total cost of tests.
Proposed methodology is applied on the data of California and Florida.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not Applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data has been procured from the github repository of Johns Hopkins University and the website of the CDC, USA.
https://github.com/CSSEGISandData/COVID-19
https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.html
